Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Startup Promotion Guide to Support Major Companies as well: MHLW Official
August 10, 2016
- JMA, MHLW Say Possible Opdivo Re-Pricing Is Emergency Step, Won’t Make It Slippery Slope to Annual Revisions
August 9, 2016
- Key Govt Panel Sets Sights on Pricy Meds
August 9, 2016
- Japanese Society of Nephrology Wins AMED Funding for “Surrogate Endpoint” Guidelines
August 8, 2016
- MHLW Panel OKs Opdivo for RCC, ASKA’s Hepatic Encephalopathy Drug
August 8, 2016
- MHLW Unveils Draft Fast-Track Scheme for Drug-Resistant Infection Treatments
August 5, 2016
- MHLW Advisory Panel Backs Nesina-Metformin Combo
August 5, 2016
- 4 Bcr-Abl TKIs Ordered to Add Risk of HBV Reactivation in Labels: MHLW
August 5, 2016
- Sovaldi Has High Unmet Medical Need for Genotype 3 Hep C: MHLW Panel
August 5, 2016
- Merck Serono Scolded over Delays in Erbitux ADR Reporting
August 4, 2016
- Kipres/Singulair to Face Generic Onslaught in Dec.; Competition to Hit Tracleer, Too
August 4, 2016
- Health Minister Shiozaki Retains Post in Cabinet Reshuffle
August 4, 2016
- MHLW Issues Alert on Teratogenic Risk of CellCept, Generic Versions: Safety Bulletin
August 3, 2016
- MHLW to Gauge Possible Deregulation of Plasma Export Restriction towards FY2018: Blood Division Chief
August 3, 2016
- MHLW Study Underway to Delineate Scope of “Essential Drugs”: Official
August 2, 2016
- Japan Should Reward Innovative Startups through Drug Prices: Report
August 2, 2016
- MHLW Releases Interim Report for Full-Fledged Rollout of MID-NET
August 1, 2016
- Compassionate Use Scheme Applied to Pfizer’s Crizotinib
August 1, 2016
- MHLW Alerts on αβ T-Cell Therapy after Opdivo
July 29, 2016
- MHLW Official Positive about Seeking Budgets to Boost PMDA Reviewers
July 29, 2016
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…